AKT1 and vascular malformation: Although we did not directly compare PIK3CAAKT1AKT2KO mice and PIK3CATie2-CreER mice treated with miransertib, we observed a severe outcome with uncontrolled disease progression in both sets of mice, accompanied by inhibited AKT phosphorylation in vascular malformations, indicating successful target engagement.